Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $294.25.
A number of research analysts have issued reports on the stock. Weiss Ratings lowered shares of Jazz Pharmaceuticals from a “hold (c+)” rating to a “hold (c-)” rating in a research note on Thursday. Wall Street Zen cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. UBS Group lifted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, August 26th. Finally, Citigroup began coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price objective on the stock.
Check Out Our Latest Stock Analysis on JAZZ
Jazz Pharmaceuticals Price Performance
Shares of NASDAQ JAZZ opened at $241.55 on Monday. Jazz Pharmaceuticals has a fifty-two week low of $139.26 and a fifty-two week high of $266.38. The company has a market cap of $15.51 billion, a PE ratio of 82.16, a P/E/G ratio of 0.44 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82. The business has a 50-day simple moving average of $229.13 and a two-hundred day simple moving average of $219.62.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.15. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. Jazz Pharmaceuticals’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $8.13 EPS. As a group, equities analysts expect that Jazz Pharmaceuticals will post 11.08 EPS for the current fiscal year.
Insider Activity at Jazz Pharmaceuticals
In other news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 1,000 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total value of $225,370.00. Following the completion of the transaction, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. This represents a 0.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 in the last quarter. 4.10% of the stock is owned by insiders.
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of large investors have recently bought and sold shares of JAZZ. L2 Asset Management LLC raised its position in Jazz Pharmaceuticals by 33.7% during the 3rd quarter. L2 Asset Management LLC now owns 36,477 shares of the specialty pharmaceutical company’s stock worth $8,445,000 after buying an additional 9,187 shares during the last quarter. FORA Capital LLC lifted its stake in Jazz Pharmaceuticals by 103.1% during the 3rd quarter. FORA Capital LLC now owns 10,984 shares of the specialty pharmaceutical company’s stock valued at $2,539,000 after acquiring an additional 5,576 shares during the period. EP Wealth Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 10.4% in the 3rd quarter. EP Wealth Advisors LLC now owns 7,049 shares of the specialty pharmaceutical company’s stock valued at $1,632,000 after acquiring an additional 664 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Jazz Pharmaceuticals by 10.7% in the 3rd quarter. Empowered Funds LLC now owns 118,280 shares of the specialty pharmaceutical company’s stock valued at $27,384,000 after acquiring an additional 11,426 shares during the last quarter. Finally, Xcelsior Advisor Partners LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $285,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
See Also
- Five stocks we like better than Jazz Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
